Key Points
- Director Kimberly Manhard sold 500 Inhibrx Biosciences shares at an average price of $110.26, generating $55,130. After the sale, she owned 8,000 shares; she also sold 500 shares in each of two earlier transactions.
- Inhibrx shares opened at $105.61, down 4.4%, with a $1.55 billion market capitalization. The company recently missed quarterly EPS expectations and analysts project a full-year loss of $9.91 per share.
- Analyst sentiment is mixed, though the stock carries a consensus “Moderate Buy” rating and a $197.50 target price. Institutional investors own 82.46% of the company.
Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) Director Kimberly Manhard sold 500 shares of the company's stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $110.26, for a total value of $55,130.00. Following the completion of the transaction, the director owned 8,000 shares in the company, valued at $882,080. This represents a 5.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Kimberly Manhard also recently made the following trade(s):
- On Friday, September 11th, Kimberly Manhard sold 500 shares of Inhibrx Biosciences stock. The stock was sold at an average price of $111.78, for a total transaction of $55,890.00.
- On Tuesday, September 8th, Kimberly Manhard sold 500 shares of Inhibrx Biosciences stock. The shares were sold at an average price of $115.14, for a total transaction of $57,570.00.
Inhibrx Biosciences Stock Down 4.4%
Inhibrx Biosciences stock opened at $105.61 on Wednesday. The firm has a market cap of $1.55 billion, a PE ratio of -11.89 and a beta of 3.66. The company has a debt-to-equity ratio of 12.58, a quick ratio of 5.07 and a current ratio of 5.07. The firm's 50 day moving average price is $99.40 and its two-hundred day moving average price is $93.82. Inhibrx Biosciences, Inc. has a twelve month low of $26.19 and a twelve month high of $155.29.
Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.28) by ($0.06). On average, research analysts predict that Inhibrx Biosciences, Inc. will post -9.91 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently issued reports on INBX shares. Citigroup reissued a "market perform" rating on shares of Inhibrx Biosciences in a research report on Thursday, August 27th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inhibrx Biosciences in a research report on Friday. HC Wainwright began coverage on Inhibrx Biosciences in a research note on Monday, August 24th. They set a "buy" rating and a $245.00 price target for the company. Finally, Wall Street Zen lowered Inhibrx Biosciences from a "hold" rating to a "strong sell" rating in a report on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Inhibrx Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $197.50.
Read Our Latest Report on INBX
Institutional Trading of Inhibrx Biosciences
Several large investors have recently modified their holdings of INBX. Integrated Wealth Concepts LLC acquired a new position in Inhibrx Biosciences in the 2nd quarter valued at $31,000. Quantbot Technologies LP acquired a new position in Inhibrx Biosciences during the 2nd quarter worth $68,000. State of Wyoming acquired a new position in Inhibrx Biosciences during the 2nd quarter worth $116,000. Hurley Capital LLC bought a new stake in Inhibrx Biosciences during the fourth quarter valued at about $131,000. Finally, Seven Fleet Capital Management LP bought a new stake in Inhibrx Biosciences during the first quarter valued at about $167,000. 82.46% of the stock is owned by institutional investors.
About Inhibrx Biosciences
(
Get Free Report)
Inhibrx Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing biologic medicines for serious diseases with limited treatment options. The company uses a proprietary protein-engineering platform to design novel therapeutic proteins, including multivalent and long-acting biologics intended to selectively affect disease-related biological pathways.
Inhibrx's development programs have included INBRX-101, also known as efzofitimod, an engineered fibroblast growth factor 1 intended for the treatment of alpha-1 antitrypsin deficiency-associated emphysema and other inflammatory lung conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
